Indigo Diabetes expands into US with Indigo Medical
Indigo Diabetes, a developer of Continuous Metabolite Monitoring (CMMTM) devices utilising nanophotonics technology, is expanding into the US via the incorporation of a fully owned subsidiary, Indigo Medical, and the appointment of Peter J. Devlin as president of the newly formed subsidiary.
The company is establishing its presence in the US, a market that it has identified as having significant potential for its CMM devices.
Devlin, who will be based in Boston, will be managing and overseeing Indigo Medical’s activities. His focus will be on accelerating product development for the company’s CMM devices, driving business development, and facilitating talent acquisition in the US. He will report directly to Danaë Delbeke, chief executive officer of Indigo.
Indigo is developing a fully implantable CMM system for people living with diabetes to access accurate information on their glucose, ketones, and lactate levels. The CMM sensor is inserted subcutaneously, preventing the need for people with diabetes to wear an external device on their body. It is designed to give people living with diabetes and their caregivers instant access to the augmented metabolic information they need to better manage their diabetes and improve therapeutic decision-making.
Peter J. Devlin, president, Indigo Medical US, said: “I have worked for many years in both in- vitro diagnostics and diabetes care and am delighted to be joining the Indigo team and leading Indigo Medical Inc. It is an exciting time for the Company to be establishing a presence in the US, particularly as the focus increases on the commercial development of our subcutaneously implanted continuous metabolite monitoring sensor.”
Dr Danaë Delbeke, chief executive officer, inventor and co-founder of Indigo Diabetes, added: “Peter has worked successfully with us as a strategic advisor for the last year, and I am very pleased that he has chosen to join us full-time to lead our newly created US subsidiary. This represents a significant market for us, and with his wealth of experience, he will play a vital role in helping us bring our first device to the US and European markets.”
Devlin has over 30 years’ experience leading the development & commercialisation of medical devices. He has worked as a strategic advisor to Indigo for the past year advising on product development, market access, and the diabetes market. Before joining Indigo, he worked for several years as an independent director and strategic advisor to early-stage medical technology companies. Prior to that he worked as the chief commercial officer of Insulet Corporation, the US medical devices company, where he led sales, marketing, business development, clinical research, and customer care operations. Whilst there, he helped develop and commercialise the OmniPod wearable insulin delivery system for people living with diabetes, leading the company to over $350 million in annual revenues.